3009 boulevard de la Concorde East
Suite 102
Laval, QC H7E 2B5
Canada
450-687-2262
https://www.acastipharma.com
版塊: Healthcare
行業: Biotechnology
全職員工:
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Prashant Kohli | CEO & Director | 358.41k | 無 | 1972 |
Mr. Robert J. DelAversano CPA | Principal Financial & Accounting Officer | 無 | 無 | 1972 |
Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer | 無 | 無 | 1962 |
Mr. Amresh Kumar Ph.D. | VP of Program Management | 無 | 無 | 1980 |
Ms. Carrie D'Andrea | VP of Clinical Operations | 無 | 無 | 1972 |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
截至 無 止,Acasti Pharma Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。